CN103251590B - Application of doxylamine succinate in preparing drug for treating or preventing influenza virus - Google Patents
Application of doxylamine succinate in preparing drug for treating or preventing influenza virus Download PDFInfo
- Publication number
- CN103251590B CN103251590B CN201310176427.2A CN201310176427A CN103251590B CN 103251590 B CN103251590 B CN 103251590B CN 201310176427 A CN201310176427 A CN 201310176427A CN 103251590 B CN103251590 B CN 103251590B
- Authority
- CN
- China
- Prior art keywords
- influenza
- virus
- doxylamine succinate
- influenza virus
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses application of doxylamine succinate in preparing a drug for treating or preventing influenza virus. The application comprises the following steps of: selecting the doxylamine succinate with complete non-toxic concentration to carry out antiviral experiment, wherein the result shows that the micromolecule compound has remarkable antiviral activity and is dose-dependent; and detecting the antiviral activity of the doxylamine succinate to different types and subtypes of influenza viruses, wherein the result indicates that the doxylamine succinate has activity for detecting virus strain, a dose-dependent effect, as well as a certain broad-spectrum to the anti-influenza virus activity. Therefore, the doxylamine succinate disclosed by the invention can be developed as a novel anti-influenza virus drug, so that a novel way and means is provided for treating the influenza.
Description
Technical field
The invention belongs to medical art, more specifically relate to the application of a kind of doxylamine succinate in preparation treatment or flu-prevention virus drugs.
Background technology
Influenza virus (influenza virus) has a strong impact on human health, can cause grippal pathogen.According to virion nucleoprotein (NP) and the antigenic characteristic of stromatin (M) and the difference of genetic characteristics, influenza virus is divided into A, B, C tri-type, also claims first, second, the third three types.All there is significant difference in the aspects such as genome structure, the polypeptide of these three kinds of veriform viruses form, infectious and pathogenic.Influenza A full-length genome is made up of the sub-thread strand RNA that 8 differ in size, and names respectively with sections 1 to sections 8.Full length viral genome is about 13.6kb, encode respectively 10 kinds of structural protein (PB2, PB1, PA, HA, NP, NA, M1, M2, PB1-F2 and NS2/NEP) and non-structural protein (NS1).According to the difference of virion surface glycoprotein hemagglutinin (HA) and neuraminidase (NA), influenza A can be further divided into 16 H (H1-H16) and 9 N (N1-N9) hypotypes.Human influenza virus is H1, H2 and H3 hypotype mainly, and endangers serious high pathogenic avian influenza at present and mostly be H5, H7 and H9 hypotype, wherein the highest with the fatality rate of H5N1 hypotype.Type B influenza virus often causes influenza localized epidemics, does not cause worldwide influenza great outburst, and in other animal except people, does not find that it exists so far.C type influenza virus exists mainly with being dispersed in form, and primary attack infant, does not generally cause influenza pandemic, can infect the mankind and pig.
Influenza virus in viral taxonomy Shang Shu orthomyxoviridae family (Orthomyxoviridae), Influenza Virus.Influenza virus is segmented minus-stranded rna virus, so viral RNA does not have infectivity, each RNA sections forms vRNPs after must combining with RNA polymerase (PB2, PB1 and PA) and nucleoprotein (NP) just has activity.Infect initial be surfaces of viral particles the identification of HA furcella and in conjunction with host cell surface contain sialic receptor.The connecting key of sialic acid and time terminal galactose, determine the host specificity of virus, this connecting key is α (2-3) in birds, is α (2-6) in the mankind.In Influenza virus HA protein molecule, the replacement of Individual amino acids and the different glycosylation modified specificitys that can change its receptors bind.After virus absorption onto cell, cell takes in virus by the receptor-mediated pinocytosis of clathrin.In cell, clathrin molecular dissociation, virus and endosome merge and form phagosome, make the pH value around virion drop to about 5.0.Under this pH condition, the conformation of viral HA protein changes, and the fusogenic peptide being positioned at light chain (HA2) N end is exposed, thus causes virus envelope and cell membrane fusion.Low pH environment also causes a large amount of H
+enter virion inside via M2 ion channel, cause dissociating of M1 albumen and vRNPs.Both common results cause the vRNPs of virion to be discharged into the endochylema of infected cell.Different from other RNA viruses, copying and transcribing of influenza virus gene group all occurs in the nucleus of host cell.MRNA transfers to endochylema after synthesizing in core, the structural protein of synthesis virus and non-structural protein.Then start to assemble progeny virus, the glycoprotein of neuraminidase hydrolyzable cell surface, release N-acetyl-neuraminate, impels virion to discharge from site of sprouting.The final step of virus maturation is that HA is cracked into HA1 and HA2 polypeptide under the effect of host protein enzyme, and such virion just has infectivity, thus starts copying of new round virus.
Influenza virus is popular in the mankind have propagated more than 300 year, and several years i.e. once outbreak of epidemic, global flu outbreak then many decades breaks out once.Influenza pandemic can cause 250,000 ~ 500,000 examples dead every year, 3,000,000 ~ 5,000,000 severe disease examples, the whole world about have 5 ~ 15% people infected.For global influenza pandemic, " in epidemic period, vaccine and antiviral drugs reduce the most important counter-measure of M & M ".But at present the whole world can produce the use of 300,000,000 person-portion trivalent flu vaccine-this only enough Hesperian influenza prevention every year, and the demand of global influenza pandemic can not be met, and due to the antigenic variation ability of influenza virus strong, can not develop vaccine before novel strain occurs.Extensive research and development and the manufacture of a usual vaccine at least need six months, even if till that time, because worldwide production is limited in one's ability and production facility concentrates on developed country, many do not have the country of production facility will use less than vaccine at the 1st ripple epidemic period.So the protective rate that current vaccines can provide is not high.Anti-influenza virus medicament not only comes out more late, and medicine quick-acting, effective is clinically also less, belongs to the little kind in anti-infection drug.At present, the anti-influenza virus medicament ratifying official listing through food and drug administration (FDA) has two classes: the M2 ion channel blocking agent that (1) is representative with amantadine and rimantadine.This type of medicine only has preventive and therapeutic action to influenza A virus, and research shows that medicine has the toxic and side effects such as neurotoxicity, and makes persister ubiquity owing to widely using, so CDC advises that this type of medicine is not used further to flu-prevention viral infection.(2) neuraminidase inhibitor, the representative of this type of medicine is oseltamivir and Zha La meter Wei.This type of medicine to all known human influenza viruses and high pathogenic avian influenza virus all effective.But the persister in recent years about oseltamivir but constantly has report.
Doxylamine succinate is histamine I class inhibitor, is the micromolecular compound of synthetic, has antihistamine effect, cholinolytic effect and significant sedation, is applicable to multiple anaphylaxis dermatosis, pollinosis, allergic rhinitis, asthmatic bronchitis etc.Also the short term therapy of medicament for the eyes for having a sleepless night can be urged.Doxylamine succinate is not had directly to be used in the application of resisiting influenza virus aspect at present.
Summary of the invention
The object of the invention is to make up the deficiencies in the prior art, be there are provided the application of a kind of micromolecular compound doxylamine succinate in preparation treatment or flu-prevention medicine, thus provide the micromolecular compound that a kind of safe and efficient toxic and side effects is little for the treatment of influenza clinically.Doxylamine succinate can effectively suppress copying of influenza virus within the scope of avirulence, can be developed as the medicine for the treatment of influenza infection disease further, be with a wide range of applications.
The English of doxylamine succinate is called doxylamine succinate, chemical formula is N, N-dimethyl-2-[1-phenyl-1-(2-pyridine) ethyoxyl] ethamine succinate (N, N-dimethyl-2-[1-phenyl-1-(pyridin-2-yl) ethoxy] ethanamine), there is the structural formula shown in structural formula I:
Structural formula I
In order to realize above-mentioned object, the present invention by the following technical solutions:
The application of a kind of doxylamine succinate in preparation treatment or flu-prevention virus (A type or B-mode) medicine, the steps include:
A. doxylamine succinate is to the cytotoxicity experiment of mdck cell: mdck cell is inoculated in 96 porocyte culture plates by 5000 cells/well (100 μ l), after cell attachment, take 2.5mM as the continuous 2 times of gradient dilutions of initial concentration 8 gradients with cell maintenance medium (DMEM+2% serum) by medicine, the multiple hole of every gradient 2, is placed in 37 DEG C, 5%CO
2cultivate in incubator after 48 hours, detect the survival rate of cell with 3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide bromine salt (tetrazolium bromide, MTT) method.Result display doxylamine succinate is to the CC50(median lethal concentration of mdck cell) be 2.08mM.
B. the evaluation of doxylamine succinate anti-influenza virus activity: mdck cell is pressed 2*10
4cells/well is inoculated in 96 porocyte culture plates, cultivates 14 ~ 18h and treats that cell grows up to monolayer, then add 100TCID in 37 DEG C of cell culture incubators
50/ hole virus liquid infection cell, gets each experimental port supernatant after adding each Concentraton gradient medicine simultaneously totally 200 μ l maintain liquid (DMEM+0.3%BSA+2.5ug/L pancreatin) cultivating 48h in 37 DEG C of cell culture incubators and carries out neuraminidase activity detection.Result shows: doxylamine succinate obviously inhibits influenza virus to copy, and its EC50 is 19.21 μMs.
C. doxylamine succinate anti-influenza virus activity broad spectrum activity is analyzed: mdck cell is pressed 2*10
4cells/well is inoculated in 96 porocyte culture plates, cultivates 14 ~ 18h and treats that cell grows up to monolayer, then add 100TCID in 37 DEG C of cell culture incubators
50/ hole virus liquid (A/human/Hubei/1/2009(H1N1), A/human/Hubei/3/2005(H3N2), InfluenzaB virus) infection cell, get each experimental port supernatant after adding each Concentraton gradient medicine simultaneously totally 200 μ l maintain liquid (DMEM+0.3%BSA+2.5ug/L pancreatin) cultivating 48h in 37 DEG C of cell culture incubators and carry out neuraminidase activity detection.Result shows: doxylamine succinate obviously can suppress subtypes of influenza A virus H1N1 strain, the copying of influenza A virus H3N2 strain and influenza B virus strain, and has dose-dependent effect.
The present invention compared with prior art has the following advantages and effect:
1. doxylamine succinate is micromolecular compound, and its CC50 is 2.08mM.Doxylamine succinate dose-dependant ground suppresses influenza virus to be copied, and its EC50 is 19.21 μMs, and therapeutic index is about 108.This illustrates that doxylamine succinate is the medicine of the efficient resisiting influenza virus of low toxicity.
2. doxylamine succinate can suppress subtypes of influenza A virus H1N1 strain, the copying of influenza A virus H3N2 strain and influenza B virus strain, and has the antiviral activity of wide spectrum.
3. utilize modern common drug preparation means, doxylamine succinate can be made the pharmaceutically acceptable dosage forms of any one such as tablet, capsule, granule, oral liquid, slow releasing preparation, controlled release preparation, nanometer formulation, injection as active components.
Accompanying drawing explanation
Fig. 1 is a kind of doxylamine succinate chemical structural formula.
Fig. 2 is that a kind of cytotoxicity of doxylamine succinate detects schematic diagram.
Fig. 3 is the neuraminidase schematic diagram alive in a kind of culture fluid supernatant of doxylamine succinate process influenza infection cell.
Fig. 4 is that a kind of doxylamine succinate anti-influenza virus activity broad spectrum activity that detects detects schematic diagram.
Fig. 4 A is subtypes of influenza A virus H1N1 strain (A/human/Hubei/1/2009(H1N1);
Fig. 4 B is influenza A virus H3N2 strain (A/human/Hubei/3/2005(H3N2);
Fig. 4 C is influenza B virus strain (Influenza B virus).
Detailed description of the invention
In order to understand content of the present invention better, below in conjunction with specific implementation method, content of the present invention is described further, but protection content of the present invention is not limited to following examples.
At present, anti-influenza virus medicament in-vitro screening model is divided into the cell free system screening model of cell culture model and viral enzyme.Enzyme reaction screening model has high-throughout feature, but the compound of screening still needs to carry out more cytology, histology and toxicity in vivo, effect experiment etc. to determine its effect.Cell culture model is the most frequently used screening model, its advantage is: the cell that a large amount of hereditary character can be provided identical is object of study, easy to operate, can eliminate the impact of other extraneous factor, and can the valid density of detection of drugs and therapeutic index, for later stage study mechanism provides more how basis.The present invention adopts cell culture screening method to detect doxylamine succinate infected by influenza infection mdck cell, detects the content of virion in viral supernatants, quantitative analysis doxylamine succinate anti-influenza virus activity.
Embodiment 1: the evaluation of doxylamine succinate anti-influenza virus activity
1. experiment material and method
1.1 cells, virus and medicine
Mdck cell is purchased from ATCC, and viral A/PR8/34H1N1 is increased by chick embryo culture and obtains, and doxylamine succinate is purchased from Sigma company;
1.2 experimental apparatus
Multi-tester PerkinElmer, inverted microscope Costar
2. experimental technique:
2.1 cell culture:
37 DEG C, 5%(volume ratio, identical below) CO
2cultivate in humidified incubator.Use containing 10%(volume ratio, identical below) penicillin of FBS, 100U/mL and the DMEM culture medium of streptomycin.Go down to posterity after cell to 90% degree of converging, the ratio that goes down to posterity 1/3 – 1/4.
2.2 Virus culture:
Get 9 ~ 11 age in days SPF Embryo Gallus domesticus, before virus inoculation, use Egg checker inspection, and at the position mark away from embryo, sterilize and punch rear by 0.2ml/ piece of inoculation 2
4the virus liquid of hemagglutinative titer, with nial polish sealing, puts 37 DEG C of calorstats and hatches 48h(and inoculate Embryo Gallus domesticus dead after 24h to be generally misoperation lethal, abandon it).Take out Embryo Gallus domesticus and put 4 DEG C of cold embryo 12h.75% alcohol disinfecting chick embryo air sac, sterile working cuts off air chamber shell, and capillary pipette draws chick embryo allantoic liquid and amniotic fluid, 3000rpm4 DEG C of centrifugal 30min, and detect hemagglutinative titer, 200 μ l/ pipe subpackage juxtapositions-70 DEG C are frozen for subsequent use.
(1) drug cytotoxicity detects:
1.MDCK cell is inoculated in 96 porocyte culture plates by 5000 cells/well (100 μ l), for subsequent use after cell attachment;
2. use cell maintenance medium (DMEM+2% serum) to be the continuous 2 times of gradient dilutions of initial concentration 6 gradients with 2.5mM by medicine, the multiple hole of every gradient 2.In every hole, add 5mg/ml MTT20 μ l after cultivating 48h, put in cell culture incubator and continue to cultivate;
3. after cultivating 4h, abandon culture fluid supernatant, every hole adds 100 μ l/ hole three lysates, and (lysate is by SDS10g, isobutanol 5ml, 10M HCl0.1ml, dissolves with distilled water and is made into 100ml), more than 4h is dissolved or enzyme connection detector detection 570nm wavelength place light absorption value after spending the night in 37 DEG C of incubators, tuning wavelength is 630nm, and calculates each drug level cell survival rate, the results are shown in Figure 2.
Result shows: doxylamine succinate does not have obvious cytotoxicity to mdck cell within the scope of concentration <625 μM, illustrates that doxylamine succinate has the safer scope of application.
(2) Activity determination of the anti-A/PR8/34H1N1 Strain of doxylamine succinate:
A. the effect of doxylamine succinate resisiting influenza virus is detected based on neuraminidase activity:
1. experimental principle: MUNANA(4-methylumbelliferyl-α-N-acetyl-neuraminate) be the specific substrate of influenza neuraminidase, the catalysate produced under neuraminidase effect is under 355nm excitation light irradiation, 460nm fluorescence can be produced, the change of fluorescence intensity, can sensitive reaction neuraminidase activity, thus can viral load in reacting cells supernatant.
2. mdck cell is pressed 2*10
4cells/well is inoculated in 96 porocyte culture plates, after cultivating 14 ~ 18h, grows up to after monolayer for subsequent use until cell in 37 DEG C of cell culture incubators.Culture medium in orifice plate is discarded, PBS liquid washes twice, add 100TCID50/ hole virus liquid infection cell, add each Concentraton gradient medicine (with 500 μMs for initial concentration simultaneously, continuous 2 times of gradient dilutions 8 gradients, the multiple hole of every gradient 2) get each experimental port supernatant after totally 200 μ l maintain liquid (DMEM+0.3%BSA+2.5ug/L pancreatin) cultivate 48h in 37 DEG C of cell culture incubators and carry out neuraminidase activity detection.
3. in the micro plate of black 96 hole, add 40 μ l buffer (32.5mmol/L MES, pH6.5,4mmol/L CaCl
2) the substrate 20umol/L MUNANA for preparing, add each experimental port culture supernatant 20 μ l again, 37 DEG C of lucifuges hatch 30min, add reaction terminating liquid (0.014 μM of NaOH, 83% ethanol) 100 μ l/ holes, multi-tester measures fluorescent value (excitation wavelength 355nm, wavelength of transmitted light 465nm).
4. calculate the suppressed rate of NA in each detect aperture.Suppression ratio (%)=100-(sample well-blank)/(enzyme contrast-blank alive) * 100%.
Result shows: doxylamine succinate obviously inhibits influenza virus to copy, and in dose-dependence (see figure 3)
Variable concentrations doxylamine succinate infected by influenza inhibition of DNA replication rate is as follows:
| Concentration (μM) | Suppression ratio (%) |
| 500 | 95.98±0.52 |
| 250 | 94.52±0.04 |
| 125 | 85.14±2.18 |
| 62.5 | 78.91±1.51 |
| 31.25 | 61.27±8.23 |
| 16 | 44.66±7.79 |
| 8 | 31.02±1.41 |
| 4 | 15.23±5.08 |
Embodiment 2: doxylamine succinate anti-influenza virus activity broad spectrum activity is studied
This experiment detects the antiviral activity of doxylamine succinate to subtypes of influenza A virus H1N1 strain, influenza A virus H3N2 strain and influenza B virus strain.
1. experiment uses Strain to comprise: A/human/Hubei/1/2009(H1N1), A/human/Hubei/3/2005(H3N2), Influenza B virus
2. mdck cell is pressed 2*10
4cells/well is inoculated in 96 porocyte culture plates, after cultivating 14 ~ 18h, grows up to after monolayer for subsequent use until cell in 37 DEG C of cell culture incubators.Culture medium in orifice plate is discarded, PBS liquid washes twice, add 100TCID50/ hole virus liquid infection cell, add each Concentraton gradient medicine (with 500 μMs for initial concentration simultaneously, continuous 2 times of gradient dilutions 8 gradients, the multiple hole of every gradient 2) get each experimental port supernatant after totally 200 μ l maintain liquid (DMEM+0.3%BSA+2.5ug/L pancreatin) cultivate 48h in 37 DEG C of cell culture incubators and carry out neuraminidase activity detection.
3. in the micro plate of black 96 hole, add 40 μ l buffer (32.5mmol/L MES, pH6.5,4mmol/L CaCl
2) the substrate 20umol/L MUNANA for preparing, add each experimental port culture supernatant 20 μ l again, 37 DEG C of lucifuges hatch 30min, add reaction terminating liquid (0.014 μM of NaOH, 83% ethanol) 100 μ l/ holes, multi-tester measures fluorescent value (excitation wavelength 355nm, wavelength of transmitted light 465nm).
4. calculate the suppressed rate of NA in each detect aperture.Suppression ratio (%)=100-(sample well-blank/(enzyme contrast-blank alive) * 100%
Result shows: doxylamine succinate obviously inhibits other strains of influenza viruses to copy, and in dose-dependence (see figure 4).Other susceptible strain inhibition of DNA replication rate of variable concentrations doxylamine succinate convection current is as follows:
Claims (1)
1. doxylamine succinate is as the application of sole active ingredient in preparation treatment or flu-prevention virus drugs; Described influenza virus is influenza A virus or Influenza B virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310176427.2A CN103251590B (en) | 2013-05-13 | 2013-05-13 | Application of doxylamine succinate in preparing drug for treating or preventing influenza virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310176427.2A CN103251590B (en) | 2013-05-13 | 2013-05-13 | Application of doxylamine succinate in preparing drug for treating or preventing influenza virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103251590A CN103251590A (en) | 2013-08-21 |
| CN103251590B true CN103251590B (en) | 2014-12-17 |
Family
ID=48956029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310176427.2A Expired - Fee Related CN103251590B (en) | 2013-05-13 | 2013-05-13 | Application of doxylamine succinate in preparing drug for treating or preventing influenza virus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103251590B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1014983A1 (en) * | 1997-09-19 | 2000-07-05 | The Procter & Gamble Company | Naproxen/cetirizine compositions and methods for treating respiratory disorders |
| JP2003012514A (en) * | 2001-07-02 | 2003-01-15 | Taisho Pharmaceut Co Ltd | Medicament composition |
| US20050266031A1 (en) * | 2004-05-25 | 2005-12-01 | Jay Dickerson | Pharmaceutical suspension composition |
-
2013
- 2013-05-13 CN CN201310176427.2A patent/CN103251590B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103251590A (en) | 2013-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kumar et al. | The emerging influenza virus threat: status and new prospects for its therapy and control | |
| CN103893171B (en) | The application of benzydamine hydrochloride in preparation treatment or flu-prevention virus infective medicament | |
| CN103239446B (en) | Application of chlorpheniramine maleate in preparation of medicaments for treating or preventing influenza virus | |
| CN110870864B (en) | Application of carbinoxamine maleate in preparation of anti-influenza virus medicine | |
| CN107898778A (en) | Application of the myricetin in anti-influenza virus medicament is prepared | |
| CN103720687B (en) | The application of dicoumarol in the medicine preparing treatment or flu-prevention viral infection | |
| CN103705506B (en) | Application of enilconazole in preparing drug for treating or preventing influenza virus infections | |
| CN103690536A (en) | Application of ciclopirox olamine in preparing medicine for treating or preventing influenza virus infection | |
| CN103705497B (en) | Application of liothyronine in preparation of medicine for treatment or prevention of influenza virus infection | |
| CN103251590B (en) | Application of doxylamine succinate in preparing drug for treating or preventing influenza virus | |
| CN103251576B (en) | Application of diphenhydramine hydrochloride in preparation of medicines for treating or preventing influenza viruses | |
| CN103705516B (en) | The application of chloroxine in the medicine preparing treatment or flu-prevention viral infection | |
| CN103251591B (en) | Application of mepyramine maleate in preparing drug for treating or preventing influenza virus | |
| CN103720684B (en) | The application of bentrl hydrothloride in preparation treatment or flu-prevention virus infective medicament | |
| CN103690517B (en) | Application of dithranol to preparation of medicament for treating or preventing influenza virus infection | |
| CN103893187B (en) | The application of trimeprimine in preparation treatment or flu-prevention virus infective medicament | |
| CN109453174B (en) | Application of effective inhibitor of type III phosphatidylinositol phosphokinase in preparation of medicine for treating or preventing influenza virus infection | |
| CN103705498A (en) | Application of fenofibrate in preparing drug for treating or preventing influenza virus infections | |
| CN103690522B (en) | Application of nafronyloxalate in preparing medicine for treating or preventing influenza virus | |
| CN103893162B (en) | The application of proadifen in preparation treatment or flu-prevention virus infective medicament | |
| CN103893175A (en) | Application of brompheniramine in preparation of medicine for treating or preventing influenza virus infection | |
| CN103705522B (en) | Application of promethazine hydrochlorine in preparation of drug for treatment or prevention of influenza virus infection | |
| CN102274206B (en) | Application of germacrone in preparation of medicament for treating or preventing influenza viruses | |
| CN108721264B (en) | Application of isoxsuprine in preparing medicine for treating or preventing influenza virus infection | |
| CN110151767B (en) | Application of GNF-7 in preparation of medicine for treating influenza virus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141217 Termination date: 20200513 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |